Dystrophin (DMD) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 133 Published: April 29, 2022 Report Code: GMDGDHC22073TDB

Dystrophin is a cytoplasmic protein, which anchors the extracellular matrix to the cytoskeleton via F-actin. It acts as ligand for dystroglycan. It also acts as component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma.

The Dystrophin – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Dystrophin, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Dystrophin and features dormant and discontinued projects.

Key Therapy Areas in the Dystrophin Pipeline Drugs Market

In the Dystrophin pipeline drugs market the key therapy areas are Genetic Disorders, and Musculoskeletal Disorders.

Dystrophin Pipeline Drugs Market, by Therapy Areas

Dystrophin Pipeline Drugs Market, by Therapy Areas

For more therapy area insights, download a free report sample

Key MoA in the Dystrophin Pipeline Drugs Market

In the Dystrophin pipeline drugs market the key MoA is Dystrophin Activator.

Dystrophin Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Dystrophin pipeline drugs market are intravenous, subcutaneous, intramuscular, and parenteral. Intravenous has the maximum number of pipeline products.

Dystrophin Pipeline Drugs Market Analysis, by RoA

Dystrophin Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Dystrophin Pipeline Drugs Market

The key molecule types in the Dystrophin pipeline drugs market are Antisense Oligonucleotide, Gene Therapy, Cell Therapy, Antisense Gene Therapy, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Oligonucleotide, and Protein.

Dystrophin Pipeline Drugs Market, by Molecule Type

Dystrophin Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the Dystrophin Pipeline Drugs Market

The major companies in the Dystrophin pipeline drugs market are Sarepta Therapeutics Inc, Astellas Gene Therapies, Avidity Biosciences Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, Editas Medicine Inc, Nippon Shinyaku Co Ltd, NS Pharma Inc, OliPass Corporation, Pepgen Ltd, Pfizer Inc, and RegenxBio Inc.

Dystrophin Pipeline Drugs Market, by Major Companies

Dystrophin Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Dystrophin Pipeline Drugs Market Overview

Key Therapy Areas Genetic Disorders, and Musculoskeletal Disorders
Key Mechanisms of action Dystrophin Activator
Key Routes of Administration Intravenous, Subcutaneous, Intramuscular, and Parenteral
Key molecule types Antisense Oligonucleotide, Gene Therapy, Cell Therapy, Antisense Gene Therapy, Monoclonal Antibody Conjugated, Gene-Modified Cell Therapy, Oligonucleotide, and Protein
Major companies Sarepta Therapeutics Inc, Astellas Gene Therapies, Avidity Biosciences Inc, Daiichi Sankyo Co Ltd, Dystrogen Therapeutics SA, Editas Medicine Inc, Nippon Shinyaku Co Ltd, NS Pharma Inc, OliPass Corporation, Pepgen Ltd, Pfizer Inc, and RegenxBio Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dystrophin
  • The pipeline guide reviews pipeline therapeutics for Dystrophin by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dystrophin therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dystrophin therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Dystrophin

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective countercstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dystrophin
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dystrophin pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Key Players

Alpha Anomeric

Astellas Gene Therapies

Avidity Biosciences Inc

Code Biotherapeutics Inc

Daiichi Sankyo Co Ltd

Dystrogen Therapeutics SA

Editas Medicine Inc

Eli Lilly and Co

Evox Therapeutics Ltd

FibroGenesis LLC

MyoGene Bio LLC

Myosana Therapeutics Inc

Nippon Shinyaku Co Ltd

NS Pharma Inc

OliPass Corporation

Pepgen Ltd

Pfizer Inc

RegenxBio Inc

Sarepta Therapeutics Inc

Solid Biosciences Inc

Sutura Therapeutics Ltd

Suzhou GenAssist Therapeutics Co Ltd

Tolerion Inc

Ultragenyx Pharmaceutical Inc

Vertex Pharmaceuticals Inc

Wave Life Sciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dystrophin (DMD) – Overview

Dystrophin (DMD) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Dystrophin (DMD) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dystrophin (DMD) – Companies Involved in Therapeutics Development

Dystrophin (DMD) – Drug Profiles

Dystrophin (DMD) – Dormant Products

Dystrophin (DMD) – Discontinued Products

Dystrophin (DMD) – Product Development Milestones

Featured News & Press Releases

Apr 07, 2022: Dystrogen Therapeutics investigational chimeric cell therapy DT-DEC01 for the treatment of Duchene Muscular Dystrophy shows safety and functional improvements

Apr 06, 2022: PepGen announces first participant dosed in a phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular Dystrophy

Mar 18, 2022: Exon 44-targeted DMD drug hits goals in PI/II: NCNP/Nippon Shinyaku

Mar 17, 2022: The result of an investigator-initiated clinical trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy

Mar 15, 2022: PepGen announces approval by Health Canada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular Dystrophy

Mar 11, 2022: The result of an investigator-initiated clinical trial (First In Human trial) of NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy

Mar 08, 2022: Roche to present new SRP-9001 data at MDA 2022 and highlight expanding neuromuscular disease portfolio

Jan 10, 2022: Sarepta Therapeutics’ Gene Therapy SRP-9001 shows statistically significant functional improvements compared to pre-specified matched external control in Part 2 of study SRP-9001-102 for the treatment of Duchenne Muscular Dystrophy

Jan 07, 2022: FDA grants IND clearance for REGENXBIO’s gene therapy trial for Duchenne

Jan 06, 2022: Sarepta Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

Nov 29, 2021: Nippon Shinyaku implements VILTEPSO managed access program

Nov 25, 2021: Addition of Viltepso to the list of Injection Drugs that physicians providing health insurance treatment can administer

Nov 22, 2021: REGENXBIO announces Orphan Drug Designation granted to RGX-202, a novel gene therapy candidate for the treatment of Duchenne Muscular Dystrophy

Oct 11, 2021: Sarepta Therapeutics’ SRP-9001 shows sustained functional improvements in multiple studies of patients with Duchenne

Oct 04, 2021: Solid Biosciences and Forge Biologics announce viral vector contract development and cGMP manufacturing partnership

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Alpha Anomeric, 2022

Pipeline by Astellas Gene Therapies, 2022

Pipeline by Avidity Biosciences Inc, 2022

Pipeline by Code Biotherapeutics Inc, 2022

Pipeline by Daiichi Sankyo Co Ltd, 2022

Pipeline by Dystrogen Therapeutics SA, 2022

Pipeline by Editas Medicine Inc, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by Evox Therapeutics Ltd, 2022

Pipeline by FibroGenesis LLC, 2022

Pipeline by MyoGene Bio LLC, 2022

Pipeline by Myosana Therapeutics Inc, 2022

Pipeline by Nippon Shinyaku Co Ltd, 2022

Pipeline by NS Pharma Inc, 2022

Pipeline by OliPass Corporation, 2022

Pipeline by Pepgen Ltd, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by RegenxBio Inc, 2022

Pipeline by Sarepta Therapeutics Inc, 2022

Pipeline by Solid Biosciences Inc, 2022

Pipeline by Sutura Therapeutics Ltd, 2022

Pipeline by Suzhou GenAssist Therapeutics Co Ltd, 2022

Pipeline by Tolerion Inc, 2022

Pipeline by Ultragenyx Pharmaceutical Inc, 2022

Pipeline by Vertex Pharmaceuticals Inc, 2022

Pipeline by Wave Life Sciences Ltd, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently Asked Questions

Enquire Before Buying
$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.